Sharma P, Hingorani A, Jia H, Ashby M, Hopper R, Clayton D, Brown M J
Clinical Pharmacology Unit, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Hypertension. 1998 Oct;32(4):676-82. doi: 10.1161/01.hyp.32.4.676.
Despite advances in the understanding of monogenic hypertensive disorders, the genetic contribution to essential hypertension has yet to be elucidated. The position of tyrosine hydroxylase (TH) as the rate-limiting enzyme in catecholamine biosynthesis renders it a candidate gene for the etiology of hypertension. The TH gene contains an internal, informative microsatellite marker (TCAT)9. We undertook (1) an association study in a group of well-characterized hypertensive subjects (HT) and control subjects (NT) and (2) an affected sibling pair (ASP) study using sibships from our local family practices. Two hundred twenty-seven hypertensive patients (pretreatment systolic/diastolic blood pressure [BP] range, 139/94 to 237/133 mm Hg; age range [SD], 30 to 71 [8.5] years) were age- and gender-matched with 206 control subjects (BP range, 96/62 to 153/86 mm Hg; age range, 40 to 70 [7.6] years). One hundred thirty-six affected sibling pairs were recruited for our linkage study; 73 young borderline hypertensive subjects (YHT) (pretreatment BP range, 123/76 to 197/107 mm Hg; age range, 20 to 51 [9.4] years) were also recruited in whom recent pretreatment norepinephrine and epinephrine levels were available. All subjects were white. The TH short tandem repeat (STR) was amplified using specific polymerase chain reaction cycling conditions in all subjects, and products were run on an ABI 373A sequencer. TH alleles were assigned using Genescan and Genotyper software. Five TH alleles were present and designated A through E. Allele frequencies in the NT population (A, B, C, D, and E: 0.24, 0.17, 0.13, 0.20, and 0.26, respectively) were significantly different from the HT cohort (A, B, C, D, and E: 0.24, 0.19, 0.11, 0.11, and 0.35, respectively), P<0. 0005 (Pearson's test chi2=19.94; 4 df). The E allele appears overrepresented in the HT group, whereas the D allele appears to be overrepresented in the NT group. TH genotype frequencies were also significantly different between cases and controls (P<0.001; chi2=36. 57; 14 df). Both groups were in Hardy-Weinberg proportion. There was a trend (NS) for the D allele to be associated with a lower BP when BP was analyzed as a quantitative trait. ASP linkage data was analyzed using Splink, a nonparametric program. Expected values for sharing 0, 1, and 2 alleles (Z0, Z1, and Z2, respectively) may be expected to be 25%, 50%, and 25%, respectively, by chance (assuming identity by descent). These probabilities were calculated by Splink as 34, 68, and 34, respectively, and compared with observed values of 36.8, 67.9, and 31.3, respectively; thus, there was no excess sharing of TH alleles among affected sibling pairs (P=0.59; logarithm of odds ratio score, 0.0). TH allele frequencies in our YHT group (A, B, C, D, and E: 0.24, 0.20, 0.12, 0.15, and 0.29, respectively) were similar to those of our NT cohort (P>0.05). There was a trend for lower pretreatment plasma norepinephrine levels with the D allele in this YHT cohort. A common and potentially functional variant at codon 81(Val-->Met) within exon 2 of the TH gene (which we show to be in linkage disequilibrium with TH-STR) was also typed in our YHT but did not associate with catecholamine levels and is therefore unlikely to account for our findings with D and E TH-STR. In conclusion, the TH locus strongly associates with essential hypertension in a case-control model using well-characterized hypertensive and control groups. An ASP linkage model was negative, presumably because of lack of power. This study suggests that the TH gene, or a nearby gene, may be involved in the etiology of essential hypertension.
尽管在单基因高血压疾病的认识上取得了进展,但遗传因素对原发性高血压的影响仍有待阐明。酪氨酸羟化酶(TH)作为儿茶酚胺生物合成中的限速酶,使其成为高血压病因的候选基因。TH基因包含一个内部信息微卫星标记(TCAT)9。我们进行了(1)一项针对一组特征明确的高血压患者(HT)和对照者(NT)的关联研究,以及(2)一项使用来自当地家庭医疗诊所的同胞对的受累同胞对(ASP)研究。227名高血压患者(治疗前收缩压/舒张压[BP]范围为139/94至237/133mmHg;年龄范围[标准差]为30至71[8.5]岁)在年龄和性别上与206名对照者匹配(BP范围为96/62至153/86mmHg;年龄范围为40至70[7.6]岁)。136对受累同胞对被招募用于我们的连锁研究;还招募了73名年轻临界高血压患者(YHT)(治疗前BP范围为123/76至197/107mmHg;年龄范围为20至51[9.4]岁),他们近期治疗前的去甲肾上腺素和肾上腺素水平可用。所有受试者均为白人。在所有受试者中使用特定的聚合酶链反应循环条件扩增TH短串联重复序列(STR),产物在ABI 373A测序仪上运行。使用Genescan和Genotyper软件确定TH等位基因。存在五个TH等位基因,分别命名为A至E。NT人群中的等位基因频率(A、B、C、D和E分别为0.24、0.17、0.13、0.20和0.26)与HT队列中的等位基因频率(A、B、C、D和E分别为0.24、0.19、0.11、0.11和0.35)有显著差异,P<0.0005(Pearson检验卡方=19.94;4自由度)。E等位基因在HT组中似乎过度表达,而D等位基因在NT组中似乎过度表达。病例组和对照组之间的TH基因型频率也有显著差异(P<0.001;卡方=36.57;14自由度)。两组均符合哈迪-温伯格比例。当将BP作为定量性状进行分析时,D等位基因有与较低BP相关的趋势(无统计学意义)。使用非参数程序Splink分析ASP连锁数据。随机情况下,共享0、1和2个等位基因(分别为Z0、Z1和Z2)的预期值可能分别为25%、50%和25%(假设同源性)。Splink计算出这些概率分别为34、68和34,与观察值分别为36.8、67.9和31.3进行比较;因此,在受累同胞对中TH等位基因没有过度共享(P=0.59;优势比得分的对数,0.0)。我们YHT组中的TH等位基因频率(A、B、C、D和E分别为0.24、0.20、0.12、0.15和0.29)与我们NT队列中的频率相似(P>0.05)。在这个YHT队列中,D等位基因有使治疗前血浆去甲肾上腺素水平降低的趋势。TH基因第2外显子中第81位密码子(Val→Met)处的一个常见且可能具有功能的变异(我们发现其与TH-STR处于连锁不平衡状态)也在我们的YHT中进行了分型,但与儿茶酚胺水平无关,因此不太可能解释我们关于D和E TH-STR的发现。总之,在使用特征明确的高血压和对照组的病例对照模型中,TH基因座与原发性高血压密切相关。ASP连锁模型为阴性,可能是因为检验效能不足。这项研究表明,TH基因或其附近的基因可能参与原发性高血压的病因。